Summit Therapeutics And MD Anderson Cancer Center Announce Five-Year Collaboration To Advance PD-1/VEGF Bispecific Ivonescimab In Multiple Clinical Trials For Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics and MD Anderson Cancer Center have announced a five-year collaboration to advance the PD-1/VEGF bispecific Ivonescimab in multiple clinical trials for solid tumors.
July 25, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Summit Therapeutics has entered a five-year collaboration with MD Anderson Cancer Center to advance the PD-1/VEGF bispecific Ivonescimab in multiple clinical trials for solid tumors.
The collaboration with a prestigious institution like MD Anderson Cancer Center is likely to boost investor confidence in Summit Therapeutics. The focus on advancing Ivonescimab in clinical trials for solid tumors could lead to significant advancements and potential market opportunities, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100